Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3939
-0.0361 (-8.39%)
Jul 15, 2025, 4:00 PM EDT - Market closed
Vaxart Employees
Vaxart had 105 employees as of December 31, 2024. The number of employees decreased by 4 or -3.67% compared to the previous year.
Employees
105
Change (1Y)
-4
Growth (1Y)
-3.67%
Revenue / Employee
$451,381
Profits / Employee
-$553,543
Market Cap
89.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VXRT News
- 4 weeks ago - Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - GlobeNewsWire
- 4 weeks ago - Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - GlobeNewsWire
- 5 weeks ago - Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewsWire
- 6 weeks ago - Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewsWire
- 6 weeks ago - Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - GlobeNewsWire
- 6 weeks ago - Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewsWire
- 6 weeks ago - Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewsWire
- 7 weeks ago - Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewsWire